Key Takeaways
- • Adcendo closed an oversubscribed $75 million Series C funding round led by Jeito Capital, with participation from ten institutional investors including Vida Ventures, Bpifrance, EIFO, RA Capital Management, TPG, OrbiMed, Venrock, Novo Holdings, and Dawn Biopharma.
- • The Copenhagen-based biotechnology company will deploy capital to advance three antibody-drug conjugate (ADC) programs targeting aggressive solid tumors with limited treatment options: ADCE-T02 (Tissue Factor-targeting ADC in Phase I expansion), ADCE-D01 (uPARAP-targeting ADC for soft tissue sarcoma), and ADCE-B05 (early-stage program for squamous cell carcinomas).
- • The funding round positions Adcendo to strengthen its clinical development pipeline and bolster prospects for a future U.S. initial public offering, according to company leadership.
- • The ADC market is experiencing rapid expansion driven by advancements in targeted delivery mechanisms and potent payloads, creating a favorable backdrop for Adcendo's pipeline advancement.
Summary
Adcendo ApS, a Copenhagen-based biotechnology company specializing in antibody-drug conjugates (ADCs) for oncology, has successfully closed a $75 million Series C financing round that exceeded investor demand. The oversubscribed round was led by Jeito Capital, a prominent life sciences investment firm, and attracted a diverse syndicate of institutional backers spanning both new and existing investors across North America and Europe.
The investor consortium included Vida Ventures, Bpifrance, the Export and Investment Fund of Denmark (EIFO), RA Capital Management, TPG, OrbiMed, Venrock, Novo Holdings, and KKR-backed Dawn Biopharma. The broad participation reflects strong institutional confidence in Adcendo's clinical strategy and therapeutic platform targeting unmet oncology needs.
The capital raise will fuel advancement of three clinical-stage ADC candidates through critical development milestones. ADCE-T02, a Tissue Factor-targeting ADC, is currently undergoing Phase I expansion studies across multiple tumor types. ADCE-D01, which targets uPARAP, is being evaluated for soft tissue sarcoma and related malignancies. The third program, ADCE-B05, targets an undisclosed antigen and is in early-stage development for squamous cell carcinomas. According to company leadership, the fresh capital also positions Adcendo to strengthen its pipeline and enhance its readiness for a future U.S. IPO.
The timing of this funding aligns with accelerating market dynamics in the ADC space, where technological improvements in targeted payload delivery have expanded clinical applications. Adcendo's focus on first- and best-in-class ADCs targeting mesenchymal solid tumors with substantial unmet medical need positions the company within a high-growth segment of oncology therapeutics development.
The investor consortium included Vida Ventures, Bpifrance, the Export and Investment Fund of Denmark (EIFO), RA Capital Management, TPG, OrbiMed, Venrock, Novo Holdings, and KKR-backed Dawn Biopharma. The broad participation reflects strong institutional confidence in Adcendo's clinical strategy and therapeutic platform targeting unmet oncology needs.
The capital raise will fuel advancement of three clinical-stage ADC candidates through critical development milestones. ADCE-T02, a Tissue Factor-targeting ADC, is currently undergoing Phase I expansion studies across multiple tumor types. ADCE-D01, which targets uPARAP, is being evaluated for soft tissue sarcoma and related malignancies. The third program, ADCE-B05, targets an undisclosed antigen and is in early-stage development for squamous cell carcinomas. According to company leadership, the fresh capital also positions Adcendo to strengthen its pipeline and enhance its readiness for a future U.S. IPO.
The timing of this funding aligns with accelerating market dynamics in the ADC space, where technological improvements in targeted payload delivery have expanded clinical applications. Adcendo's focus on first- and best-in-class ADCs targeting mesenchymal solid tumors with substantial unmet medical need positions the company within a high-growth segment of oncology therapeutics development.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.